Trial Profile
An Open-label Study of the Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2016
Price :
$35
*
At a glance
- Drugs Gevokizumab (Primary)
- Indications Labyrinthitis
- Focus Therapeutic Use
- Sponsors XOMA
- 05 Aug 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 21 Nov 2014 New trial record